1803 related articles for article (PubMed ID: 27591074)
1. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.
Unger MM; Spiegel J; Dillmann KU; Grundmann D; Philippeit H; Bürmann J; Faßbender K; Schwiertz A; Schäfer KH
Parkinsonism Relat Disord; 2016 Nov; 32():66-72. PubMed ID: 27591074
[TBL] [Abstract][Full Text] [Related]
2. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease.
Aho VTE; Houser MC; Pereira PAB; Chang J; Rudi K; Paulin L; Hertzberg V; Auvinen P; Tansey MG; Scheperjans F
Mol Neurodegener; 2021 Feb; 16(1):6. PubMed ID: 33557896
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota are related to Parkinson's disease and clinical phenotype.
Scheperjans F; Aho V; Pereira PA; Koskinen K; Paulin L; Pekkonen E; Haapaniemi E; Kaakkola S; Eerola-Rautio J; Pohja M; Kinnunen E; Murros K; Auvinen P
Mov Disord; 2015 Mar; 30(3):350-8. PubMed ID: 25476529
[TBL] [Abstract][Full Text] [Related]
4. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
Chen SJ; Chen CC; Liao HY; Lin YT; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
Neurology; 2022 Feb; 98(8):e848-e858. PubMed ID: 34996879
[TBL] [Abstract][Full Text] [Related]
5. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors.
de la Cuesta-Zuluaga J; Mueller NT; Álvarez-Quintero R; Velásquez-Mejía EP; Sierra JA; Corrales-Agudelo V; Carmona JA; Abad JM; Escobar JS
Nutrients; 2018 Dec; 11(1):. PubMed ID: 30591685
[TBL] [Abstract][Full Text] [Related]
6. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
Sun MF; Shen YQ
Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
Yang X; Ai P; He X; Mo C; Zhang Y; Xu S; Lai Y; Qian Y; Xiao Q
Mov Disord; 2022 Aug; 37(8):1634-1643. PubMed ID: 35607987
[TBL] [Abstract][Full Text] [Related]
8. Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features.
Li W; Wu X; Hu X; Wang T; Liang S; Duan Y; Jin F; Qin B
Sci China Life Sci; 2017 Nov; 60(11):1223-1233. PubMed ID: 28536926
[TBL] [Abstract][Full Text] [Related]
9. Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD Trial.
Becker A; Schmartz GP; Gröger L; Grammes N; Galata V; Philippeit H; Weiland J; Ludwig N; Meese E; Tierling S; Walter J; Schwiertz A; Spiegel J; Wagenpfeil G; Faßbender K; Keller A; Unger MM
Genomics Proteomics Bioinformatics; 2022 Apr; 20(2):274-287. PubMed ID: 34839011
[TBL] [Abstract][Full Text] [Related]
10. Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study.
Chu JR; Kang SY; Kim SE; Lee SJ; Lee YC; Sung MK
World J Gastroenterol; 2019 Oct; 25(40):6129-6144. PubMed ID: 31686768
[TBL] [Abstract][Full Text] [Related]
11. Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson's disease.
Li F; Wang P; Chen Z; Sui X; Xie X; Zhang J
Neurosci Lett; 2019 Aug; 707():134297. PubMed ID: 31200089
[TBL] [Abstract][Full Text] [Related]
12. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
13. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism.
Morrison DJ; Preston T
Gut Microbes; 2016 May; 7(3):189-200. PubMed ID: 26963409
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
[TBL] [Abstract][Full Text] [Related]
15. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics.
Tan AH; Chong CW; Lim SY; Yap IKS; Teh CSJ; Loke MF; Song SL; Tan JY; Ang BH; Tan YQ; Kho MT; Bowman J; Mahadeva S; Yong HS; Lang AE
Ann Neurol; 2021 Mar; 89(3):546-559. PubMed ID: 33274480
[TBL] [Abstract][Full Text] [Related]
16. A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
Mulak A
Mov Disord; 2018 Mar; 33(3):398-401. PubMed ID: 29436731
[No Abstract] [Full Text] [Related]
17. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Lai F; Jiang R; Xie W; Liu X; Tang Y; Xiao H; Gao J; Jia Y; Bai Q
Neurochem Res; 2018 Oct; 43(10):1986-1999. PubMed ID: 30171422
[TBL] [Abstract][Full Text] [Related]
18. More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota.
Mertsalmi TH; Aho VTE; Pereira PAB; Paulin L; Pekkonen E; Auvinen P; Scheperjans F
Eur J Neurol; 2017 Nov; 24(11):1375-1383. PubMed ID: 28891262
[TBL] [Abstract][Full Text] [Related]
19. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.
Bedarf JR; Hildebrand F; Coelho LP; Sunagawa S; Bahram M; Goeser F; Bork P; Wüllner U
Genome Med; 2017 Apr; 9(1):39. PubMed ID: 28449715
[TBL] [Abstract][Full Text] [Related]
20. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels.
Valcheva R; Koleva P; Martínez I; Walter J; Gänzle MG; Dieleman LA
Gut Microbes; 2019; 10(3):334-357. PubMed ID: 30395776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
